Navigation Links
Fifteenth US Patent Issued for aTyr Pharma Novel Biotherapeutic
Date:9/9/2009

SAN DIEGO, Sept. 9 /PRNewswire/ -- aTyr Pharma announced today that the US Patent office has issued patent US 7,572,452 B2, titled "Method for Stimulating Wound Healing." aTyr Pharma is the sole assignee of this patent, and Professor Sunghoon Kim, a scientific co-founder of aTyr Pharma, is the inventor. An example of aTyr Pharma's broad intellectual property portfolio and the fifteenth filed patent related to aTyr Pharma's work in tRNA synthetases, this patent covers new extracellular activities for p43, a critical protein component of the multi-aminoacyl tRNA synthetase complex in humans. The aminoacyl tRNA synthetases are universal and essential elements of the protein synthesis machinery found in all organisms, but human synthetases and their associated proteins have naturally occurring resected variants, called "resectins," with potent cell signaling activities that are vital to normal functioning of humans. The resectins' activities are distinct from the protein synthesis activities commonly known for synthetases, and aTyr Pharma is discovering and developing the resectins as new biotherapeutic agents that can be used to treat a wide variety of human diseases including inflammatory, autoimmune, hematopoietic and metabolic disorders.

Jeff Watkins, CEO of aTyr Pharma, had this to say about the patent: "This patent covers discoveries Professor Kim has made for extracellular activity of the p43 component of the multi-sythetase complex. As part of aTyr Pharma's portfolio, this patent helps establish our dominant ownership and leadership in the resectin space. Capitalizing on this new area of biology, we are identifying and developing these naturally occurring resectins as candidate biotherapeutics for treating a wide variety of diseases."

Professor Kim, of Seoul National University in Korea, has had a long scientific relationship with Professor Paul Schimmel of The Scripps Research Institute and a co-founder of aTyr Pharma. According to Professor Schimmel, "Professor Kim's research has really helped build our understanding of how far-reaching the non-canonical functions are for naturally occurring resectins of tRNA synthetases and their associated proteins. This newly issued patent highlights the innovation surrounding the discovery and development of tRNA synthetase resectins as biotherapeutics." Professors Schimmel and Kim recently co-authored a scientific article in the Proceedings of the Natural Academy of Sciences (PNAS USA, 2008, vol. 105: 11043-11409) describing many of the newly emerging functions of tRNA synthetases and the relationships to human medicine.

Link to the PNAS review article: http://www.pnas.org/content/105/32/11043.full.pdf

About aTyr Pharma

aTyr Pharma, Inc. is a biopharmaceutical company focused on the discovery and development of an entirely new class of biologics. aTyr Pharma's discovery engine for new biotherapeutics consists of novel proteins in the family of tRNA synthetases with cell signaling activities distinct from the protein synthesis activities commonly associated with the tRNA synthetases. These resected proteins, or "resectins," are being developed as novel therapeutics to treat hematological disorders, neurodegenerative diseases, inflammation, cardiovascular diseases and metabolic disorders.

www.atyrpharma.com


'/>"/>
SOURCE aTyr Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Fifteenth Annual Pridelights Goes Green
2. Genova files patent for new prostate cancer treatment
3. Caraco Pharmaceutical Laboratories, Ltd. Announces Reversal of Summary Judgment in Ultracet(R) ANDA Patent Litigation
4. TANCS Steam Vapor Granted U.S. Patent
5. Milestone Scientific Announces Notice of Allowance From US Patent and Trademark Office
6. Palomar Successful in U.S. Patent Office Re-Examination of Second Hair Removal Patent
7. Secure eHealth Partner Receives Patent and Notice of Patent Allowance that is Key to Enriched Data Portability in Healthcare
8. U.S. District Court Rules Against Lilly Regarding Gemzar Patent
9. Hard To Treat Diseases (HTDS.PK) Completes IP Ownership Filings With U.S. Patent and Trademark Office
10. German District Court Rules in Smith & Nephews Favor in Patent Infringement Case
11. AlphaRx Receives China Patent on Its Drug Delivery Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... Advanced Spine ... to help restore its patients’ health, is hosting a free seminar on stem cell ... be held at Advanced Spine & Sport, 4601 Telephone Road, Suite 110, Ventura, CA. ...
(Date:5/4/2016)... ... 04, 2016 , ... Mediware Information Systems, Inc . ... that helps blood and marrow transplant (BMT) programs meet compliance and accreditation standards ... continued to enhance core application features. These enhancements are designed to help BMT ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... Scientific Group is scheduled on July 25-27, 2016 at Las Vegas. It aims ... care professionals from educational institutes and research organizations across the globe; making the ...
(Date:5/3/2016)... ... , ... The National Association of Professional Women (NAPW) honors ... Circle. She is recognized with this prestigious distinction for leadership in business. NAPW is ... and over 200 operating Local Chapters. , “I’m pleased to welcome Barbara into this ...
(Date:5/3/2016)... ... , ... Sue Desmond-Hellmann, chief executive officer of the Bill & Melinda Gates ... possibility in her keynote address at Georgia State University’s spring commencement on ... rich experience as a scientist, physician and executive, Desmond-Hellmann leads the Gates Foundation’s efforts ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... -- Intec Pharma Ltd. (NASDAQ: ... announced the appointment of Pnina Strauss-Levy as ... Strauss-Levy has 15 years of experience in clinical research ... record, having supported the advancement of several products through ... the United States and ...
(Date:5/3/2016)... 3, 2016 Norgine ... sie einen entscheidenden Meilenstein durch diese Veröffentlichung ... zum Handeln, um Patientenresultate  bei Verdauungs- und ... Fortschritten im Verständnis der Hepatischen Enzephalopathie bei ... für Hepatische Enzephalopathie in der Öffentlichkeit zu ...
(Date:5/2/2016)... 2, 2016  Deerfield announced today it led ... Vision, Inc. Graybug Vision is an early stage ... transform care for ocular diseases including wet age-related ... was first developed at Johns Hopkins University and ... Graybug Vision is developing ophthalmology ...
Breaking Medicine Technology: